Marc Olivier Perret
Marc Olivier Perret joined Gilde in 2000 from Ciba/Novartis. Prior to joining in October 2000, Marc Olivier gained operational and international experience during 17 years at the Novartis (Ciba) Group, in business development, restructuring, as country division head and ultimately as M&A Head of one of Novartis’ divisions.
His track record includes a $ 1 billion acquisition of a Merck & Co division, direct involvement in the multi-billion merger and listing of Switzerland-based Syngenta, and several smaller biotechnology deals.
Marc Olivier Perret is an engineer from École Centrale de Lyon and received an M.B.A. from HEC Group/Stanford Graduate School of Business.
He is a French national and speaks English, Italian and Spanish. Marc Olivier led investments in Conatus Pharmaceuticals (listed at NASDAQ), Innate Pharma (listed at Euronext) and Neuro3D (merged). Former board representations include CropDesign (sold to BASF), Conatus Pharmaceuticals, Neuro3d and Innate Pharma.